Coherus BioSciences Inc represents a set of core values and a corporate philosophy that guide its operations. The company is committed to bringing high-quality and cost-effective biosimilar therapies to patients. With a focus on innovation, Coherus BioSciences aims to improve access to important treatments and enhance patients' quality of life. By fostering a collaborative working environment, the company encourages creativity and teamwork among its employees. Coherus BioSciences also prioritizes integrity, transparency, and ethical behavior in its business practices. Through its dedication to patients, innovation, and values-driven approach, Coherus BioSciences Inc strives to make a positive impact in the pharmaceutical industry.

Coherus BioSciences Inc is primarily present in the United States, with its headquarters located in Redwood City, California. As a leading global biosimilar company, Coherus BioSciences Inc focuses on developing and commercializing high-quality therapeutics that expand patient access to important medicines. While the company's primary presence is in the US, it also possesses a growing international footprint. With a commitment to improving patient lives worldwide, Coherus BioSciences Inc continues to expand its reach and impact in various countries and regions to provide innovative treatment options for a range of medical conditions.

Some significant milestones achieved by Coherus BioSciences Inc include the successful completion of clinical trials for their biosimilar products and securing regulatory approvals for their medications. The company has also expanded its portfolio through partnerships and collaborations with other pharmaceutical companies. Furthermore, Coherus BioSciences Inc has achieved reimbursement agreements for their biosimilar products, ensuring broader access to affordable treatments. These milestones demonstrate the company's commitment to advancing biosimilar therapies and improving patient access to high-quality, cost-effective medications.

Coherus BioSciences Inc, founded in 2010, is a leading biotechnology company focused on the development and commercialization of high-quality biosimilar therapeutics. Headquartered in Redwood City, California, Coherus is dedicated to expanding patient access to essential and cost-effective treatments. With expertise in drug development, manufacturing, and commercialization, the company has successfully launched biosimilar products in multiple therapeutic areas. Coherus is committed to improving patient lives by providing affordable and reliable medications. It is recognized as a key player in the global biopharmaceutical industry, delivering innovative solutions to meet healthcare challenges.

Some of the main competitors of Coherus BioSciences Inc in the market include big players such as Amgen Inc., Pfizer Inc., and Novartis AG. These companies also operate within the pharmaceutical sector and compete in the development and commercialization of biosimilar drugs. While Coherus BioSciences Inc aims to offer cost-effective alternatives to expensive biologic drugs, it faces competition from these industry giants who also have significant market shares and resources. Being aware of the competitive landscape is important for investors and stakeholders to understand the dynamics within the market for Coherus BioSciences Inc.

Coherus BioSciences Inc is primarily active in the biotechnology and pharmaceutical industries.

The business model of Coherus BioSciences Inc. is focused on developing and commercializing high-quality biosimilar therapeutics. As a leading global biosimilar company, Coherus is dedicated to providing patients with access to affordable treatment options. By leveraging their expertise in biologic drug development, Coherus aims to develop biosimilars that are highly similar to reference products in terms of safety, efficacy, and quality. This business model allows Coherus to contribute to the reduction of healthcare costs while maintaining a commitment to improving patient outcomes.

Coherus BioSciences hissesinin F/K oranı -0,94.

Coherus BioSciences KUV 0,48 dir.

Coherus BioSciences için AlleAktien Kalite Skoru 4/10'dur.

beklenen Coherus BioSciences cirosu 273,07 Milyon. USD dir.

beklenen Coherus BioSciences karı -139,26 Milyon. USD olarak gerçekleşmiştir.

Coherus BioSciences Inc is an emerging biotechnology company specializing in the development and commercialization of high-quality biosimilars. The company's business model is based on providing cost-effective and accessible treatment options for patients suffering from cancer, inflammatory diseases, and other serious illnesses. Coherus BioSciences is headquartered in Redwood City, California, and is listed on the NASDAQ Global Market under the ticker symbol "CHRS". Coherus BioSciences has an extensive pipeline of biosimilars in various stages of development. A biosimilar is a biological medicine that has similar properties to an already approved biological medicine. Biosimilars can generally be produced and offered at a lower cost than the original product. Coherus BioSciences has already successfully launched some biosimilars on the market, such as the Adalimumab biosimilar UDENYCA® for the treatment of rheumatoid arthritis, Crohn's disease, and psoriasis. Coherus BioSciences' business model also includes collaborations with other major pharmaceutical companies such as Pfizer and Daiichi-Sankyo. These partnerships enable Coherus BioSciences to access resources and technologies to accelerate and improve the development of biosimilars. Through its partnerships, Coherus BioSciences is also able to expand its global presence in the market and penetrate into new geographical regions. The company has an extensive product pipeline, which includes several biosimilars in various stages of development. Some of the key products currently being developed by Coherus BioSciences are biosimilars of Pegfilgrastim, Bevacizumab, and Etanercept. Pegfilgrastim is used for the prevention of infections in patients receiving chemotherapy, while Bevacizumab is used for the treatment of various types of cancer. Etanercept is used for the treatment of rheumatoid arthritis and psoriasis. Coherus BioSciences also has a business model focused on expanding its operations into other therapeutic areas such as cancer and inflammatory diseases. The company also plans to expand into new geographical regions to strengthen its global presence and increase its revenues and profits. In 2021, the company expanded its presence in the European market with the launch of UDENYCA® and another biosimilar as part of its partnership with Baxalta. In summary, Coherus BioSciences' business model is aimed at providing cost-effective treatment options for patients with serious illnesses. The company specializes in the development and sale of biosimilars and has an extensive product pipeline in various stages of development. Coherus BioSciences also works closely with major pharmaceutical companies to expand its operations and strengthen its global presence.

Coherus BioSciences, yılda kez dağıtılmak üzere 0 USD tutarında temettü ödemektedir.

Coherus BioSciences için şu an için temettü hesaplanamıyor veya şirket temettü dağıtmıyor.

Coherus BioSciences şirketinin ISIN kodu US19249H1032’dir.

Coherus BioSciences 'nin WKN'si A12ETZ 'dir.

Coherus BioSciences için Ticker CHRS’dir.

Son 12 ay içerisinde Coherus BioSciences, tutarında bir temettü ödedi. Bu, yaklaşık olarak oranında bir temettü verimine denk gelmektedir. Gelecek 12 ay için Coherus BioSciences, tahmini olarak 0 USD tutarında bir temettü ödemesi yapacak.

Coherus BioSciences şirketinin mevcut temettü verimi .

Coherus BioSciences dönemsel olarak temettü ödemesi yapar. Bu ödemeler aylarında gerçekleştirilir.

Coherus BioSciences, son 0 yıl içerisinde her yıl temettü ödedi.

Önümüzdeki 12 ay için 0 USD tutarında temettü ödenmesi beklenmektedir. Bu, 0 % oranında bir temettü verimidir.

Coherus BioSciences, 'Sağlık' sektörüne atanmıştır.

Son Coherus BioSciences tarihinde 0 USD tutarındaki en son temettüyü alabilmek için, hisseyi 26.08.2024 tarihindeki Ex-Tag'den önce portföyünde bulundurman gerekiyordu.

Son ödeme tarihi 26.08.2024 olarak gerçekleşti.

2023 yılında Coherus BioSciences tarafından 0 USD olarak temettüler dağıtıldı.

Coherus BioSciences hisselerinin temettüleri USD olarak dağıtılır.